AbCellera Biologics (ABCL) Set to Announce Quarterly Earnings on Monday

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) is scheduled to be releasing its earnings data after the market closes on Monday, November 4th. Analysts expect AbCellera Biologics to post earnings of ($0.14) per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. AbCellera Biologics had a negative net margin of 463.77% and a negative return on equity of 13.40%. The business had revenue of $7.30 million for the quarter, compared to analyst estimates of $10.12 million. During the same period last year, the firm earned ($0.11) earnings per share. AbCellera Biologics's revenue for the quarter was down 27.7% compared to the same quarter last year. On average, analysts expect AbCellera Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AbCellera Biologics Stock Up 6.3 %

Shares of ABCL traded up $0.17 during mid-day trading on Monday, hitting $2.89. 2,850,234 shares of the company's stock were exchanged, compared to its average volume of 1,620,860. AbCellera Biologics has a 52 week low of $2.34 and a 52 week high of $6.05. The stock's 50-day simple moving average is $2.61 and its 200-day simple moving average is $3.10. The firm has a market cap of $849.82 million, a price-to-earnings ratio of -5.56 and a beta of 0.38.

Wall Street Analyst Weigh In

ABCL has been the topic of a number of recent analyst reports. Benchmark cut AbCellera Biologics from a "buy" rating to a "hold" rating in a research report on Tuesday, August 20th. KeyCorp restated an "overweight" rating and set a $5.00 target price (down from $7.00) on shares of AbCellera Biologics in a research note on Thursday, July 11th.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.